(2R)-daptomycin

Also known as N-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon(1)-lactone, N-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine 1.13-3.4-lactone, LY 146032, daptomycin, CBC134

Daptomycin, sold under the brand name Cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.

Key facts

Drug.ChEBI: 600103
Drug.ChEMBL: 508162
Drug.O: 26
Drug.Verifiedfields: changed
Drug.Watchedfields: changed
Drug.verifiedrevid: 457630808
Drug.image: Daptomycin Ball et al.svg
Drug.image_class: skin-invert-image
Drug.width: 300
Drug.tradename: Cubicin, Cubicin RF, Dapzura RT
Drug.DailyMedID: Daptomycin
Drug.pregnancy_AU: B1
Drug.routes_of_administration

Article

12 sections

Contents

Medical uses
Adverse effects
Pharmacology
Mechanism of action
Microbiology
Daptomycin resistance
Efficacy
Biosynthesis
History
References
Further reading
External links

Daptomycin, sold under the brand name Cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.

Daptomycin was removed from the World Health Organization's List of Essential Medicines in 2019. The World Health Organization classifies daptomycin as critically important for human medicine.